ReviewJournal of the American Society of Nephrology : JASN2016
Idiopathic Retroperitoneal Fibrosis.
Review in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Treatment approaches for idiopathic retroperitoneal fibrosis: a systematic review with meta-analysis.BMC rheumatology · 2025Pooled it
- Clinical characteristics and multimodal imaging insights of coronary involvement in immunoglobulin G4-related disease.Frontiers in immunology · 2025Pooled it
- Drugs associated with retroperitoneal fibrosis: assessment of the 1969-2025 Food and Drug Administration (FDA) pharmacovigilance database.Pharmacological reports : PR · 2026Article
- Idiopathic IgG4-negative perivascular fibrosis with extensive thoracic aortic, coronary artery, and supra-aortic branch involvement: A case report.Radiology case reports · 2026Article
- Improvement of Lymphedema in IgG4-Related Disease with Oral Glucocorticoid Therapy.Internal medicine (Tokyo, Japan) · 2026Article
- Not just two roads down: a multimodality radiologic-pathologic review of ureteral diseases.Abdominal radiology (New York) · 2026Review
- Clinical features, diagnosis, and management of retroperitoneal fibrosis in a university referral hospital and literature review.Internal and emergency medicine · 2026Review
- Comparable effectiveness of intensive intravenous and less intensive immunosuppressive treatment in retroperitoneal fibrosis: a retrospective real-world cohort study.Rheumatology international · 2026Observational
- Benchmarking LLM decision support in inflammatory aneurysms: DeepSeek-R1, DeepSeek-V3 and ChatGPT-4o.Clinical and experimental medicine · 2026Article
- Retroperitoneal Fibrosis Presenting With Duodenal Obstruction: A Fatal Case of Corticosteroid-Resistant Disease.Cureus · 2026Article
- Postpartum Retroperitoneal Fibrosis With IVC Obstruction: A Case Report.Case reports in radiology · 2026Article
- Article
- Pharmacological treatment of idiopathic retroperitoneal fibrosis.Reumatologia · 2026Review
- Antineutrophil Cytoplasmic Autoantibodies Specific to Bactericidal/Permeability-Increasing Protein: A Cross-Road Between Prolonged Gram-Negative Bacterial Infections and Ulcerative Colitis/Primary Sclerosing Cholangitis.Diagnostics (Basel, Switzerland) · 2025Article
- Multimodality imaging review of retroperitoneal fibrosis.Abdominal radiology (New York) · 2025Review
- Article
- IgG4-related disease and other fibro-inflammatory conditions.Nature reviews. Rheumatology · 2025Review
- Article
- Systemic lupus erythematosus complicated by retroperitoneal fibrosis: A case report and literature review.Medicine · 2025Review
- Relapse Predictors of Idiopathic Retroperitoneal Fibrosis: A Long-Term Cohort Study.Pragmatic and observational research · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic retroperitoneal fibrosis (RPF), reviewed herein, is a rare fibro-inflammatory disease that develops around the abdominal aorta and the iliac arteries, and spreads into the adjacent retroperitoneum, where it frequently causes ureteral obstruction and renal failure. The clinical phenotype of RPF is complex, because it can be associated with fibro-inflammatory disorders involving other organs, is considered part of the spectrum of IgG4-related disease, and often arises in patients with other autoimmune conditions. Obstructive uropathy is the most common complication, although other types of renal involvement may occur, including stenosis of the renal arteries and veins, renal atrophy, and different types of associated GN. Environmental and genetic factors contribute to disease susceptibility, whereas the immunopathogenesis of RPF is mediated by different immune cell types that eventually promote fibroblast activation. The diagnosis is made on the basis of computed tomography or magnetic resonance imaging, and positron emission tomography is a useful tool in disease staging and follow-up. Treatment of idiopathic RPF aims at relieving ureteral obstruction and inducing disease regression, and includes the use of glucocorticoids, combined or not with other traditional immunosuppressants. However, biologic therapies such as the B cell-depleting agent rituximab are emerging as potentially efficacious agents in difficult-to-treat cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.